#United States #Los Angeles #Cancer Research #pancreatic cancer #PanCAN

Recent Statistics on Pancreatic Cancer

A recent report published by the American Cancer Society in its 2025 Cancer Statistics reveals alarming trends regarding pancreatic cancer. The five-year relative survival rate for this type of cancer remains stagnant at only 13%, a number that is particularly disheartening when considering the rise in diagnoses and mortality rates over the past few years. For individuals diagnosed with pancreatic adenocarcinoma, the most prevalent form, the survival rate drops even further to just 8%.

Despite a nationwide decline in overall cancer mortality rates, pancreatic cancer has become increasingly deadly, currently ranking as the third leading cause of cancer-related deaths in the United States. The prognosis appears grim, with estimates of 67,440 new diagnoses and 51,980 deaths expected in a single year, demonstrating the urgency of addressing this crisis.

Disparities in Survival Rates

Notably, the survival rates are even lower for specific demographics. African Americans diagnosed with pancreatic cancer face a five-year survival rate of approximately 11%, reflecting a broader pattern of discrepancies in cancer outcomes across various racial and ethnic groups.

Dr. Anna Berkenblit, Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network (PanCAN), comments on the lack of progress, stating, "While we have seen incremental progress in treatment, it is disheartening that pancreatic cancer remains the only major cancer type with a survival rate below 20%." She emphasizes that the slight improvement in survival numbers may stem from an increase in incidental findings of less aggressive neuroendocrine tumors, underscoring an urgent need for focused screening and treatment strategies targeting pancreatic adenocarcinoma.

The Need for Research and Better Treatments

To combat these rising statistics, there is a pressing need for enhanced research funding aimed at early detection methods and the development of advanced treatments for pancreatic cancer. PanCAN aims to increase the five-year survival rate to 20% by 2030, necessitating innovative solutions that hinge on research breakthroughs.

An innovative approach that PanCAN is pursuing is establishing a connection between high blood sugar levels and pancreatic cancer. The organization has launched an Early Detection Initiative to develop a screening method capable of identifying pancreatic cancer at a stage where it can be surgically removed.

Moreover, the recent approval of several new drugs targeted at treating diabetes and obesity—both associated risk factors for pancreatic cancer—raises hopes for future advancements in treatment. The advent of precision medicine, which customizes therapies based on individual patient profiles, is also beginning to yield promising results in the management of this of often deadly disease.

Empowering Patients and Families

PanCAN not only advances the field of pancreatic cancer research but also prioritizes the needs of patients and their families. Recognized as a leading organization in this arena, PanCAN provides support and resources to those affected by pancreatic cancer. Their team of trained professionals offers educational materials and services at no cost to ensure that patients and families have the necessary tools to advocate for their healthcare.

For updated details on pancreatic cancer research, patient support services, and ongoing initiatives, the public is encouraged to visit PanCAN’s official website at pancan.org. Additionally, PanCAN can be followed on social media platforms like X, Instagram, and Facebook to stay informed about their latest efforts and achievements.

In conclusion, while the landscape for pancreatic cancer presents significant challenges, there is unwavering hope for progress through enhanced research initiatives and increased awareness. Fighting against pancreatic cancer requires a collective approach, and organizations like PanCAN are at the forefront of this vital mission.